Clinical Trial Results:
Exploration of TNF-alpha Blockade with golimumab in the Induction of Clinical Remission in Patients with Early peripheral SpondyloArthritis (SpA) according to ASAS-criteria (‘CRESPA’).
Summary
|
|
EudraCT number |
2011-003678-97 |
Trial protocol |
BE |
Global end of trial date |
30 Apr 2019
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
19 Sep 2021
|
First version publication date |
19 Sep 2021
|
Other versions |
Trial Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
|
|||
Trial identification
|
|||
Sponsor protocol code |
AGO/2011/005
|
||
Additional study identifiers
|
|||
ISRCTN number |
- | ||
US NCT number |
- | ||
WHO universal trial number (UTN) |
- | ||
Sponsors
|
|||
Sponsor organisation name |
Ghent University Hospital
|
||
Sponsor organisation address |
Corneel Heymanslaan 10, Ghent, Belgium, 9000
|
||
Public contact |
Hiruz CTU, Ghent University Hospital, 32 93320500, hiruz.ctu@uzgent.be
|
||
Scientific contact |
Hiruz CTU, Ghent University Hospital, 32 93320500, hiruz.ctu@uzgent.be
|
||
Paediatric regulatory details
|
|||
Is trial part of an agreed paediatric investigation plan (PIP) |
No
|
||
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial? |
No
|
||
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial? |
No
|
||
Results analysis stage
|
|||
Analysis stage |
Final
|
||
Date of interim/final analysis |
07 May 2019
|
||
Is this the analysis of the primary completion data? |
Yes
|
||
Primary completion date |
19 Mar 2019
|
||
Global end of trial reached? |
Yes
|
||
Global end of trial date |
30 Apr 2019
|
||
Was the trial ended prematurely? |
No
|
||
General information about the trial
|
|||
Main objective of the trial |
To explore the potential of an induction therapy with the TNF-blocking agent golimumab (Simponi® in a very early disease stage (less than 3 months of symptom duration) of patients with predominant peripheral Spondyloarthritis (SpA), classified according to the new ASAS-criteria.
In the open-label ‘CRESPA-extension’ part of the study, we want to investigate the long-term safety and efficacy of golimumab administered every 4 weeks at a dose of 50 mg subcutaneously (SC) for a total period of 116 weeks (104 weeks golimumab monotherapy + 12 weeks combination therapy with methotrexate 10-15 mg weekly).
|
||
Protection of trial subjects |
Ethics review and approval, informed consent, supportive care and routine monitoring.
|
||
Background therapy |
- | ||
Evidence for comparator |
- | ||
Actual start date of recruitment |
01 Oct 2011
|
||
Long term follow-up planned |
Yes
|
||
Long term follow-up rationale |
Safety | ||
Long term follow-up duration |
29 Months | ||
Independent data monitoring committee (IDMC) involvement? |
No
|
||
Population of trial subjects
|
|||
Number of subjects enrolled per country |
|||
Country: Number of subjects enrolled |
Belgium: 60
|
||
Worldwide total number of subjects |
60
|
||
EEA total number of subjects |
60
|
||
Number of subjects enrolled per age group |
|||
In utero |
0
|
||
Preterm newborn - gestational age < 37 wk |
0
|
||
Newborns (0-27 days) |
0
|
||
Infants and toddlers (28 days-23 months) |
0
|
||
Children (2-11 years) |
0
|
||
Adolescents (12-17 years) |
0
|
||
Adults (18-64 years) |
60
|
||
From 65 to 84 years |
0
|
||
85 years and over |
0
|
|
||||||||||||||||
Recruitment
|
||||||||||||||||
Recruitment details |
84 patients were screened in the period from 01-10-2011 till 18-03-2019. 60 patients were included, 60 patients were randomised. 59 patients were included and completed the trial. End of trial notification was dated 18-03-2019 (last patient last visit) and submitted to EC and CA 23-05-2019. | |||||||||||||||
Pre-assignment
|
||||||||||||||||
Screening details |
Inclusion Criteria: - ≥ 18 years of age - meet the new Assessment of SpondyloArthritis (ASAS) criteria for peripheral spondyloarthritis: -1 of the Peripheral Spondyloarthritis (SpA) features - Onset of peripheral SpA symptoms ≤ 3 months prior to the screening visit - active disease at screening and baseline | |||||||||||||||
Period 1
|
||||||||||||||||
Period 1 title |
Baseline
|
|||||||||||||||
Is this the baseline period? |
Yes | |||||||||||||||
Allocation method |
Randomised - controlled
|
|||||||||||||||
Blinding used |
Double blind | |||||||||||||||
Roles blinded |
Subject, Investigator | |||||||||||||||
Blinding implementation details |
The randomisation and blinding was completely performed by Theorem Clinical Research. The decision to unblind a patient will be made by the study physician and was extensively documented in the patient file. Theorem Clinical Research provided sealed envelopes which were kept in the clinical study master file at the department of Rheumatology, University Hospital Gent.
|
|||||||||||||||
Arms
|
||||||||||||||||
Are arms mutually exclusive |
Yes
|
|||||||||||||||
Arm title
|
Baseline CRESPA study: Placebo | |||||||||||||||
Arm description |
- | |||||||||||||||
Arm type |
Active comparator | |||||||||||||||
Investigational medicinal product name |
Placebo
|
|||||||||||||||
Investigational medicinal product code |
||||||||||||||||
Other name |
||||||||||||||||
Pharmaceutical forms |
Solution for injection in pre-filled syringe
|
|||||||||||||||
Routes of administration |
Subcutaneous use
|
|||||||||||||||
Dosage and administration details |
The prefilled syringe with golimumab or placebo will be administrated subcutaneously every 4 weeks.
|
|||||||||||||||
Arm title
|
Baseline CRESPA study: Golimumab 50mg (Simponi®) | |||||||||||||||
Arm description |
- | |||||||||||||||
Arm type |
Experimental | |||||||||||||||
Investigational medicinal product name |
Simponi
|
|||||||||||||||
Investigational medicinal product code |
CAS 476181-74-5
|
|||||||||||||||
Other name |
golimumab
|
|||||||||||||||
Pharmaceutical forms |
Solution for injection in pre-filled syringe
|
|||||||||||||||
Routes of administration |
Subcutaneous use
|
|||||||||||||||
Dosage and administration details |
The prefilled syringe with golimumab or placebo will be administrated subcutaneously every 4 weeks.
|
|||||||||||||||
|
||||||||||||||||
Period 2
|
||||||||||||||||
Period 2 title |
CERPA Study
|
|||||||||||||||
Is this the baseline period? |
No | |||||||||||||||
Allocation method |
Randomised - controlled
|
|||||||||||||||
Blinding used |
Double blind | |||||||||||||||
Roles blinded |
Subject, Investigator | |||||||||||||||
Arms
|
||||||||||||||||
Are arms mutually exclusive |
Yes
|
|||||||||||||||
Arm title
|
CRESPA study: Placebo | |||||||||||||||
Arm description |
- | |||||||||||||||
Arm type |
Active comparator | |||||||||||||||
Investigational medicinal product name |
Placebo
|
|||||||||||||||
Investigational medicinal product code |
||||||||||||||||
Other name |
||||||||||||||||
Pharmaceutical forms |
Solution for injection in pre-filled syringe
|
|||||||||||||||
Routes of administration |
Subcutaneous use
|
|||||||||||||||
Dosage and administration details |
The prefilled syringe with golimumab or placebo will be administrated subcutaneously every 4 weeks.
|
|||||||||||||||
Arm title
|
CRESPA study: Golimumab 50mg (Simponi®) | |||||||||||||||
Arm description |
- | |||||||||||||||
Arm type |
Experimental | |||||||||||||||
Investigational medicinal product name |
Simponi
|
|||||||||||||||
Investigational medicinal product code |
CAS 476181-74-5
|
|||||||||||||||
Other name |
golimumab
|
|||||||||||||||
Pharmaceutical forms |
Solution for injection in pre-filled syringe
|
|||||||||||||||
Routes of administration |
Subcutaneous use
|
|||||||||||||||
Dosage and administration details |
The prefilled syringe with golimumab or placebo will be administrated subcutaneously every 4 weeks.
|
|||||||||||||||
|
||||||||||||||||
Period 3
|
||||||||||||||||
Period 3 title |
CERPA extension
|
|||||||||||||||
Is this the baseline period? |
No | |||||||||||||||
Allocation method |
Not applicable
|
|||||||||||||||
Blinding used |
Not blinded | |||||||||||||||
Arms
|
||||||||||||||||
Arm title
|
Treatment arm | |||||||||||||||
Arm description |
The ‘CRESPA-Extension’ part of the study is designed to investigate safety and long-term efficacy of golimumab in peripheral SpA patients with a major response to golimumab or a disease flare upon withdrawal of golimumab after reaching initial remission in the ‘CRESPA’ study. In the last 3 months of the CRESPA-Extension study part, golimumab treatment will be combined with methotrexate in order to explore the possibility that co-medication with methotrexate would allow for the discontinuation of golimumab treatment at week 116, thus providing clues of the potential of “biological-free” remission. 29 were not included in the extension study because of remission. | |||||||||||||||
Arm type |
Experimental | |||||||||||||||
Investigational medicinal product name |
Ledertrexate
|
|||||||||||||||
Investigational medicinal product code |
||||||||||||||||
Other name |
Methotrexate
|
|||||||||||||||
Pharmaceutical forms |
Tablet
|
|||||||||||||||
Routes of administration |
Oral use
|
|||||||||||||||
Dosage and administration details |
Methotrexate will be administered orally with a total weekly dosage of 10 to 15 mg, meaning 4 to 6 tablets of 2.5mg weekly (104 weeks golimumab monotherapy + 12 weeks combination therapy with methotrexate 10-15 mg weekly).
|
|||||||||||||||
Investigational medicinal product name |
Simponi
|
|||||||||||||||
Investigational medicinal product code |
CAS 476181-74-5
|
|||||||||||||||
Other name |
golimumab
|
|||||||||||||||
Pharmaceutical forms |
Solution for injection in pre-filled syringe
|
|||||||||||||||
Routes of administration |
Subcutaneous use
|
|||||||||||||||
Dosage and administration details |
The prefilled syringe with golimumab or placebo will be administrated subcutaneously every 4 weeks (104 weeks golimumab monotherapy + 12 weeks combination therapy with
methotrexate 10-15 mg weekly).
|
|||||||||||||||
|
||||||||||||||||
Notes [1] - The number of subjects starting the period is not consistent with the number completing the preceding period. It is expected the number of subjects starting the subsequent period will be the same as the number completing the preceding period. Justification: 29 were not included in the extension study because of remission. |
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Baseline characteristics reporting groups
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Baseline CRESPA study: Placebo
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
- | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Baseline CRESPA study: Golimumab 50mg (Simponi®)
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
- | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
|||
End points reporting groups
|
|||
Reporting group title |
Baseline CRESPA study: Placebo
|
||
Reporting group description |
- | ||
Reporting group title |
Baseline CRESPA study: Golimumab 50mg (Simponi®)
|
||
Reporting group description |
- | ||
Reporting group title |
CRESPA study: Placebo
|
||
Reporting group description |
- | ||
Reporting group title |
CRESPA study: Golimumab 50mg (Simponi®)
|
||
Reporting group description |
- | ||
Reporting group title |
Treatment arm
|
||
Reporting group description |
The ‘CRESPA-Extension’ part of the study is designed to investigate safety and long-term efficacy of golimumab in peripheral SpA patients with a major response to golimumab or a disease flare upon withdrawal of golimumab after reaching initial remission in the ‘CRESPA’ study. In the last 3 months of the CRESPA-Extension study part, golimumab treatment will be combined with methotrexate in order to explore the possibility that co-medication with methotrexate would allow for the discontinuation of golimumab treatment at week 116, thus providing clues of the potential of “biological-free” remission. 29 were not included in the extension study because of remission. |
|
||||||||||
End point title |
Clinical Remission Status at week 24 | |||||||||
End point description |
The primary endpoint of the study is the induction of clinical remission (complete resolution of synovitis/dactylitis/enthesitis which was present at baseline) and prevention of newly developing peripheral and/or axial spondylarthritis signs). The primary analysis will be a comparison at 24 weeks of the percentage of patients in clinical remission in the group treated with the Tumor Necrosis Factor (TNF)-blocking agent versus placebo.
|
|||||||||
End point type |
Primary
|
|||||||||
End point timeframe |
At week 24
|
|||||||||
|
||||||||||
Statistical analysis title |
Clinical Remission Status | |||||||||
Comparison groups |
CRESPA study: Placebo v CRESPA study: Golimumab 50mg (Simponi®)
|
|||||||||
Number of subjects included in analysis |
60
|
|||||||||
Analysis specification |
Pre-specified
|
|||||||||
Analysis type |
superiority | |||||||||
P-value |
< 0.001 | |||||||||
Method |
Fisher exact | |||||||||
Confidence interval |
|
|||||||||||||||||||||
End point title |
Patient global assessment of disease activity at week 24 | ||||||||||||||||||||
End point description |
|||||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||||
End point timeframe |
At week 24
|
||||||||||||||||||||
|
|||||||||||||||||||||
Statistical analysis title |
PGA of disease activity | ||||||||||||||||||||
Comparison groups |
Baseline CRESPA study: Golimumab 50mg (Simponi®) v Baseline CRESPA study: Placebo v CRESPA study: Placebo v CRESPA study: Golimumab 50mg (Simponi®)
|
||||||||||||||||||||
Number of subjects included in analysis |
120
|
||||||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||||||
Analysis type |
superiority | ||||||||||||||||||||
P-value |
< 0.001 | ||||||||||||||||||||
Method |
Wilcoxon (Mann-Whitney) | ||||||||||||||||||||
Confidence interval |
|
|||||||||||||||||||||
End point title |
Patient global assessment of pain at week 24 | ||||||||||||||||||||
End point description |
|||||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||||
End point timeframe |
At week 24
|
||||||||||||||||||||
|
|||||||||||||||||||||
Statistical analysis title |
PGA of pain | ||||||||||||||||||||
Comparison groups |
Baseline CRESPA study: Placebo v Baseline CRESPA study: Golimumab 50mg (Simponi®) v CRESPA study: Placebo v CRESPA study: Golimumab 50mg (Simponi®)
|
||||||||||||||||||||
Number of subjects included in analysis |
120
|
||||||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||||||
Analysis type |
superiority | ||||||||||||||||||||
P-value |
< 0.001 | ||||||||||||||||||||
Method |
Wilcoxon (Mann-Whitney) | ||||||||||||||||||||
Confidence interval |
|
|||||||||||||||||||||
End point title |
The improvement in the tender joint count at week 24 | ||||||||||||||||||||
End point description |
|||||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||||
End point timeframe |
At week 24
|
||||||||||||||||||||
|
|||||||||||||||||||||
Statistical analysis title |
tender joint count | ||||||||||||||||||||
Comparison groups |
Baseline CRESPA study: Placebo v Baseline CRESPA study: Golimumab 50mg (Simponi®) v CRESPA study: Placebo v CRESPA study: Golimumab 50mg (Simponi®)
|
||||||||||||||||||||
Number of subjects included in analysis |
120
|
||||||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||||||
Analysis type |
superiority | ||||||||||||||||||||
P-value |
< 0.001 | ||||||||||||||||||||
Method |
Wilcoxon (Mann-Whitney) | ||||||||||||||||||||
Confidence interval |
|
|||||||||||||||||||||
End point title |
The improvement in the swollen joint count at week 24 | ||||||||||||||||||||
End point description |
|||||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||||
End point timeframe |
At week 24
|
||||||||||||||||||||
|
|||||||||||||||||||||
Statistical analysis title |
swollen joint count | ||||||||||||||||||||
Comparison groups |
CRESPA study: Placebo v CRESPA study: Golimumab 50mg (Simponi®) v Baseline CRESPA study: Placebo v Baseline CRESPA study: Golimumab 50mg (Simponi®)
|
||||||||||||||||||||
Number of subjects included in analysis |
120
|
||||||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||||||
Analysis type |
superiority | ||||||||||||||||||||
P-value |
< 0.001 | ||||||||||||||||||||
Method |
Wilcoxon (Mann-Whitney) | ||||||||||||||||||||
Confidence interval |
|
||||||||||||||||
End point title |
The improvement in dactylitis at week 24 | |||||||||||||||
End point description |
||||||||||||||||
End point type |
Secondary
|
|||||||||||||||
End point timeframe |
At week 24
|
|||||||||||||||
|
||||||||||||||||
Statistical analysis title |
patients with dactylitis | |||||||||||||||
Comparison groups |
Baseline CRESPA study: Placebo v Baseline CRESPA study: Golimumab 50mg (Simponi®) v CRESPA study: Placebo v CRESPA study: Golimumab 50mg (Simponi®)
|
|||||||||||||||
Number of subjects included in analysis |
120
|
|||||||||||||||
Analysis specification |
Pre-specified
|
|||||||||||||||
Analysis type |
superiority | |||||||||||||||
P-value |
= 0.003 | |||||||||||||||
Method |
Fisher exact | |||||||||||||||
Confidence interval |
|
||||||||||||||||
End point title |
The improvement in enthesitis at week 24 | |||||||||||||||
End point description |
||||||||||||||||
End point type |
Secondary
|
|||||||||||||||
End point timeframe |
At week 24
|
|||||||||||||||
|
||||||||||||||||
Statistical analysis title |
Patients with enthesitis | |||||||||||||||
Comparison groups |
Baseline CRESPA study: Placebo v Baseline CRESPA study: Golimumab 50mg (Simponi®) v CRESPA study: Placebo v CRESPA study: Golimumab 50mg (Simponi®)
|
|||||||||||||||
Number of subjects included in analysis |
119
|
|||||||||||||||
Analysis specification |
Pre-specified
|
|||||||||||||||
Analysis type |
superiority | |||||||||||||||
P-value |
< 0.001 | |||||||||||||||
Method |
Fisher exact | |||||||||||||||
Confidence interval |
|
||||||||||
End point title |
Patients achieving Peripheral Spondyloarthritis Response Criteria pSpARC 40 at week 24 | |||||||||
End point description |
||||||||||
End point type |
Secondary
|
|||||||||
End point timeframe |
At week 24
|
|||||||||
|
||||||||||
Statistical analysis title |
pSpARC 40% | |||||||||
Comparison groups |
CRESPA study: Placebo v CRESPA study: Golimumab 50mg (Simponi®)
|
|||||||||
Number of subjects included in analysis |
60
|
|||||||||
Analysis specification |
Pre-specified
|
|||||||||
Analysis type |
superiority | |||||||||
P-value |
= 0.011 | |||||||||
Method |
Fisher exact | |||||||||
Confidence interval |
|
||||||||||
End point title |
Patients achieving Peripheral Spondyloarthritis Response Criteria pSpARC 50 at week 24 | |||||||||
End point description |
||||||||||
End point type |
Secondary
|
|||||||||
End point timeframe |
At week 24
|
|||||||||
|
||||||||||
Statistical analysis title |
pSpARC 50% | |||||||||
Comparison groups |
CRESPA study: Placebo v CRESPA study: Golimumab 50mg (Simponi®)
|
|||||||||
Number of subjects included in analysis |
60
|
|||||||||
Analysis specification |
Pre-specified
|
|||||||||
Analysis type |
superiority | |||||||||
P-value |
= 0.005 | |||||||||
Method |
Fisher exact | |||||||||
Confidence interval |
|
||||||||||
End point title |
Patients achieving Peripheral Spondyloarthritis Response Criteria pSpARC 70 at week 24 | |||||||||
End point description |
||||||||||
End point type |
Secondary
|
|||||||||
End point timeframe |
At week 24
|
|||||||||
|
||||||||||
Statistical analysis title |
pSpARC 70% | |||||||||
Comparison groups |
CRESPA study: Placebo v CRESPA study: Golimumab 50mg (Simponi®)
|
|||||||||
Number of subjects included in analysis |
60
|
|||||||||
Analysis specification |
Pre-specified
|
|||||||||
Analysis type |
superiority | |||||||||
P-value |
= 0.077 | |||||||||
Method |
Fisher exact | |||||||||
Confidence interval |
|
|||||||||||||||||||||
End point title |
Patient global assessment of disease activity at week 12 | ||||||||||||||||||||
End point description |
|||||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||||
End point timeframe |
At week 12
|
||||||||||||||||||||
|
|||||||||||||||||||||
Notes [1] - 40 |
|||||||||||||||||||||
Statistical analysis title |
PGA of disease activity | ||||||||||||||||||||
Comparison groups |
Baseline CRESPA study: Placebo v Baseline CRESPA study: Golimumab 50mg (Simponi®) v CRESPA study: Placebo v CRESPA study: Golimumab 50mg (Simponi®)
|
||||||||||||||||||||
Number of subjects included in analysis |
120
|
||||||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||||||
Analysis type |
superiority | ||||||||||||||||||||
P-value |
= 0.002 | ||||||||||||||||||||
Method |
Wilcoxon (Mann-Whitney) | ||||||||||||||||||||
Confidence interval |
|
|||||||||||||||||||||
End point title |
Patient global assessment of pain at week 12 | ||||||||||||||||||||
End point description |
|||||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||||
End point timeframe |
At week 12
|
||||||||||||||||||||
|
|||||||||||||||||||||
Statistical analysis title |
PGA of pain | ||||||||||||||||||||
Comparison groups |
Baseline CRESPA study: Placebo v Baseline CRESPA study: Golimumab 50mg (Simponi®) v CRESPA study: Placebo v CRESPA study: Golimumab 50mg (Simponi®)
|
||||||||||||||||||||
Number of subjects included in analysis |
120
|
||||||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||||||
Analysis type |
superiority | ||||||||||||||||||||
P-value |
< 0.001 | ||||||||||||||||||||
Method |
Wilcoxon (Mann-Whitney) | ||||||||||||||||||||
Confidence interval |
|
|||||||||||||||||||||
End point title |
The improvement in the tender joint count at week 12 | ||||||||||||||||||||
End point description |
|||||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||||
End point timeframe |
At week 12
|
||||||||||||||||||||
|
|||||||||||||||||||||
Statistical analysis title |
tender joint count | ||||||||||||||||||||
Comparison groups |
Baseline CRESPA study: Placebo v Baseline CRESPA study: Golimumab 50mg (Simponi®) v CRESPA study: Placebo v CRESPA study: Golimumab 50mg (Simponi®)
|
||||||||||||||||||||
Number of subjects included in analysis |
120
|
||||||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||||||
Analysis type |
superiority | ||||||||||||||||||||
P-value |
= 0.001 | ||||||||||||||||||||
Method |
Wilcoxon (Mann-Whitney) | ||||||||||||||||||||
Confidence interval |
|
|||||||||||||||||||||
End point title |
The improvement in the swollen joint count at week 12 | ||||||||||||||||||||
End point description |
|||||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||||
End point timeframe |
At week 12
|
||||||||||||||||||||
|
|||||||||||||||||||||
Statistical analysis title |
swollen joint count | ||||||||||||||||||||
Comparison groups |
Baseline CRESPA study: Placebo v Baseline CRESPA study: Golimumab 50mg (Simponi®) v CRESPA study: Placebo v CRESPA study: Golimumab 50mg (Simponi®)
|
||||||||||||||||||||
Number of subjects included in analysis |
120
|
||||||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||||||
Analysis type |
superiority | ||||||||||||||||||||
P-value |
< 0.001 | ||||||||||||||||||||
Method |
Wilcoxon (Mann-Whitney) | ||||||||||||||||||||
Confidence interval |
|
||||||||||||||||
End point title |
The improvement in dactylitis at week 12 | |||||||||||||||
End point description |
||||||||||||||||
End point type |
Secondary
|
|||||||||||||||
End point timeframe |
At week 12
|
|||||||||||||||
|
||||||||||||||||
Statistical analysis title |
Patients with dactylitis | |||||||||||||||
Comparison groups |
Baseline CRESPA study: Golimumab 50mg (Simponi®) v CRESPA study: Placebo v Baseline CRESPA study: Placebo v CRESPA study: Golimumab 50mg (Simponi®)
|
|||||||||||||||
Number of subjects included in analysis |
120
|
|||||||||||||||
Analysis specification |
Pre-specified
|
|||||||||||||||
Analysis type |
superiority | |||||||||||||||
P-value |
= 0.004 | |||||||||||||||
Method |
Fisher exact | |||||||||||||||
Confidence interval |
|
||||||||||||||||
End point title |
The improvement in enthesitis at week 12 | |||||||||||||||
End point description |
||||||||||||||||
End point type |
Secondary
|
|||||||||||||||
End point timeframe |
At week 12
|
|||||||||||||||
|
||||||||||||||||
Statistical analysis title |
Patients with enthesitis | |||||||||||||||
Comparison groups |
Baseline CRESPA study: Placebo v Baseline CRESPA study: Golimumab 50mg (Simponi®) v CRESPA study: Placebo v CRESPA study: Golimumab 50mg (Simponi®)
|
|||||||||||||||
Number of subjects included in analysis |
120
|
|||||||||||||||
Analysis specification |
Pre-specified
|
|||||||||||||||
Analysis type |
superiority | |||||||||||||||
P-value |
= 0.48 | |||||||||||||||
Method |
Fisher exact | |||||||||||||||
Confidence interval |
|
||||||||||
End point title |
Patients achieving Peripheral Spondyloarthritis Response Criteria pSpARC 40 at week 12 | |||||||||
End point description |
||||||||||
End point type |
Secondary
|
|||||||||
End point timeframe |
At week 12
|
|||||||||
|
||||||||||
Statistical analysis title |
pSpARC 40% | |||||||||
Comparison groups |
CRESPA study: Golimumab 50mg (Simponi®) v CRESPA study: Placebo
|
|||||||||
Number of subjects included in analysis |
60
|
|||||||||
Analysis specification |
Pre-specified
|
|||||||||
Analysis type |
superiority | |||||||||
P-value |
= 0.007 | |||||||||
Method |
Fisher exact | |||||||||
Confidence interval |
|
||||||||||
End point title |
Patients achieving Peripheral Spondyloarthritis Response Criteria pSpARC 50 at week 12 | |||||||||
End point description |
||||||||||
End point type |
Secondary
|
|||||||||
End point timeframe |
At week 12
|
|||||||||
|
||||||||||
Statistical analysis title |
pSpARC 50% | |||||||||
Comparison groups |
CRESPA study: Placebo v CRESPA study: Golimumab 50mg (Simponi®)
|
|||||||||
Number of subjects included in analysis |
60
|
|||||||||
Analysis specification |
Pre-specified
|
|||||||||
Analysis type |
superiority | |||||||||
P-value |
= 0.013 | |||||||||
Method |
Fisher exact | |||||||||
Confidence interval |
|
||||||||||
End point title |
Patients achieving Peripheral Spondyloarthritis Response Criteria pSpARC 70 at week 12 | |||||||||
End point description |
||||||||||
End point type |
Secondary
|
|||||||||
End point timeframe |
At week 12
|
|||||||||
|
||||||||||
Statistical analysis title |
pSpARC 70% | |||||||||
Comparison groups |
CRESPA study: Placebo v CRESPA study: Golimumab 50mg (Simponi®)
|
|||||||||
Number of subjects included in analysis |
60
|
|||||||||
Analysis specification |
Pre-specified
|
|||||||||
Analysis type |
superiority | |||||||||
P-value |
= 0.011 | |||||||||
Method |
Fisher exact | |||||||||
Confidence interval |
|
||||||||||
End point title |
Bath AS Disease Activity Index (BASDAI) 50% response | |||||||||
End point description |
||||||||||
End point type |
Secondary
|
|||||||||
End point timeframe |
At 24 weeks
|
|||||||||
|
||||||||||
Statistical analysis title |
BASDAI 50% response | |||||||||
Comparison groups |
CRESPA study: Placebo v CRESPA study: Golimumab 50mg (Simponi®)
|
|||||||||
Number of subjects included in analysis |
60
|
|||||||||
Analysis specification |
Pre-specified
|
|||||||||
Analysis type |
superiority | |||||||||
P-value |
< 0.05 | |||||||||
Method |
Fisher exact | |||||||||
Confidence interval |
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Adverse events information
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Timeframe for reporting adverse events |
Overall study
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Assessment type |
Non-systematic | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dictionary used for adverse event reporting
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dictionary name |
MedDRA | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dictionary version |
18.1
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting groups
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
CRESPA study: Placebo
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
- | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
CRESPA study: Golimumab 50mg (Simponi®)
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
- | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Frequency threshold for reporting non-serious adverse events: 0% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
|||
Substantial protocol amendments (globally) |
|||
Were there any global substantial amendments to the protocol? Yes | |||
Date |
Amendment |
||
20 Jun 2012 |
Amendment 2:
reasons for the substantial amendment: French ICF and questionnaire |
||
17 Apr 2013 |
Amendment 3:
Reasons for the substantial amendment: Rescue medication sulfasalazine/corticosteroid injections will be replaced by Golimumab 50 mg sc.
Description:
Starting at week 12 and until week 20, there will be an option to start rescue medication (in total 6 injections) with Golimumab 50mg sc every 4 weeks if all criteria for starting rescue medication are met.
Reasons for the substantial amendment: Rescue medication sulfasalazine/corticosteroid injections will be replaced by Golimumab 50 mg sc.
Description:
In case of clinical relapse (after having reached "sustained clinical remission" at 2 consecutive visits), patients will have the option to receive open-label treatment with golimumab at a dose of 50 mg SC every 4 weeks. For this "relapse treatment phase" the open-label study medication (6 injections planned for visits week 24-44) will be used.
Reasons for the substantial amendment: Visits at week 60 and 72 are extra. Investigators wish to clinically evaluate the patients a while longer. |
||
05 Aug 2013 |
Amendment 4:
Reasons for the substantial amendment: A 2-year open-label extension study to explore the long-term safety and efficacy of golimumab 50 mg SC every 4 weeks in patients that experienced major improvement of a clinical flare after achieving initial clinical remission.
Description:
Exploration of TNF-alpha blockade with golimumab in the induction of clinical remission in patients with early peripheral spondyloarthitis (SpA) according to ASAS-criteria. (‘CRESPA’), including a 2-year open-label extension study to explore the long-term safety and efficacy of golimumab 50 mg SC every 4 weeks in patients that experienced major improvement of a clinical flare after achieving initial clinical remission (‘CRESPA-extension’).
In the open-label ‘CRESPA-extension’ part of the study, we want to investigate the long-term safety and efficacy of golimumab administered every 4 weeks at a dose of 50 mg subcutaneously (SC).
Subjects will be allowed to participate in the ‘CRESPA-Extension’ part of the study if they are considered good candidates for chronic anti-TNF treatment and fulfill one of the following 2 scenarios:
|
||
26 Feb 2015 |
Amendment 5:
reasons for the substantial amendment: Changes in conduct or management of the trial
-Patients that are already more than one year in drug-free remission are considered to be in stable sustained remission and will not be entered in the CRESPA extension part of the study anymore. However, for patients that are already in drug-free remission for more than one year at the time of approval of version 6.0 of the protocol, a transitional measure will be applicable which allows them to still enter the CRESPA extension for a period of up to 2 years after reaching initial clinical remission.
-Adding of an ultrasound evaluation at the last visit of the CRESPA extension part.
-Additional info on labeling for the extension study; The open-label Golimumab syringes will be delivered by Theorem to the Ghent University Hospital Department of Rheumatology (via the Ghent University Hospital Pharmacy) in bulk with a global label. Individual syringes will be labeled study-specific following the hospital law by the Ghent University Hospital Pharmacy before dispensing to the patients.
|
||
08 Feb 2016 |
Amendment 6
Reasons for the substantial amendment:
- Changes in safety or integrity of trial subjects
- Changes in interpretation of scientific documents/value of the trial
- Changes in conduct or management of the trial
Description:
- A 12 weeks combination therapy with methotrexate 10-15 mg weekly was added in the open-label CRESPA extension part.
- Clarification of the primary analysis: The primary analysis will be a comparison at 24 weeks of the percentage of patients in clinical remissionin the group treated with the TNF-blocking agent versus placebo (for patients who were treated via the open-label Golimumab escape arm, an approach based upon last observation carried forward (LOCF) and non-responder imputation (NRI) will be used).
- There will be a comparison at 12 (and if applicable at 24) weeks of the percentage of patients with a PSpARC 40 response in the group treated with the TNF-blocking agent versus placebo.
- Changes were made to the secondary endpoints
- Three months of follow-up after CRESPA-extension: After receiving 104 weeks of open label monotherapy with golimumab 50 mg SC every 4 weeks in the CRESPA–extension study part, the patients will be offered an additional 12 weeks of open label golimumab 50 mg SC every 4 weeks, but now in combination with methotrexate. After these 12 weeks methotrexate therapy will be continued (if well tolerated), but golimumab will be stopped and the patients will further receive appropriate follow-up according to current best clinical practice guidelines for the treatment of (axial and/or peripheral) spondyloarthritis. As before, clinical evaluations, patient reported outcomes and laboratory evaluations will be recorded in the local registry for spondyloarthritis (Be-GIANT).
|
||
Interruptions (globally) |
|||
Were there any global interruptions to the trial? No | |||
Limitations and caveats |
|||
Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data. | |||
None reported | |||
Online references |
|||
http://www.ncbi.nlm.nih.gov/pubmed/28213565 |